- Home
- TLPH vs TNON Comparison
TLPH vs TNON Comparison
Compare TLPH & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- TNON
- Stock Information
- Founded
- TLPH 2005
- TNON 2012
- Country
- TLPH United States
- TNON United States
- Employees
- TLPH N/A
- TNON N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- TNON Medical Specialities
- Sector
- TLPH Health Care
- TNON Health Care
- Exchange
- TLPH Nasdaq
- TNON Nasdaq
- Market Cap
- TLPH 11.1M
- TNON 11.5M
- IPO Year
- TLPH 2011
- TNON 2022
- Fundamental
- Price
- TLPH $0.94
- TNON $1.17
- Analyst Decision
- TLPH Strong Buy
- TNON Strong Buy
- Analyst Count
- TLPH 1
- TNON 2
- Target Price
- TLPH $6.00
- TNON $5.50
- AVG Volume (30 Days)
- TLPH 4.3M
- TNON 269.5K
- Earning Date
- TLPH 11-12-2025
- TNON 11-12-2025
- Dividend Yield
- TLPH N/A
- TNON N/A
- EPS Growth
- TLPH N/A
- TNON N/A
- EPS
- TLPH N/A
- TNON N/A
- Revenue
- TLPH $27,000.00
- TNON $2,947,000.00
- Revenue This Year
- TLPH N/A
- TNON $43.52
- Revenue Next Year
- TLPH $14,533.26
- TNON $82.14
- P/E Ratio
- TLPH N/A
- TNON N/A
- Revenue Growth
- TLPH N/A
- TNON N/A
- 52 Week Low
- TLPH $0.38
- TNON $0.85
- 52 Week High
- TLPH $1.20
- TNON $7.51
- Technical
- Relative Strength Index (RSI)
- TLPH 75.75
- TNON 44.55
- Support Level
- TLPH $0.88
- TNON $1.13
- Resistance Level
- TLPH $1.20
- TNON $1.26
- Average True Range (ATR)
- TLPH 0.13
- TNON 0.07
- MACD
- TLPH 0.03
- TNON -0.01
- Stochastic Oscillator
- TLPH 62.70
- TNON 26.09
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.